Key Takeaways Alnylam and Roche reported positive phase II KARDIA-3 data on zilebesiran in hypertension patients.The 300 mg dose reduced SBP at 3 and 6 months, sustaining effects throughout the 24-hour cycle.Zilebesiran showed biomarker improvements and a mild-to-moderate safety profile, supporting phase III plans.Alnylam Pharmaceuticals (ALNY) and partner, Roche (RHHBY) , reported positive results from a mid-stage study, evaluating the efficacy and safety of zilebesiran in patients with uncontrolled hypert ...